How to buy BeyondSpring stock (BYSI)

BeyondSpring is a biotechnology business based in the US. BeyondSpring shares (BYSI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.59 – a decrease of 3.05% over the previous week. BeyondSpring employs 36 staff and has a trailing 12-month revenue of around $1.9 million.

Our top picks for where to buy BeyondSpring stock

Buy BeyondSpring stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

BeyondSpring stock price (NASDAQ: BYSI)

Use our graph to track the performance of BYSI stocks over time.

BeyondSpring shares at a glance

• Key figures

Information last updated 2024-12-15.

Latest market close	$1.59
52-week range	$0.78 - $4.00
50-day moving average more info button	$2.18
200-day moving average more info button	$2.24
Wall St. target price	$1.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.40

Is it a good time to buy BeyondSpring stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BeyondSpring price performance over time

Historical closes compared with the close of $1.59 from 2024-12-20

1 week (2024-12-13)	-3.05%
1 month (2024-11-22)	-8.62%
3 months (2024-09-20)	-25.35%
6 months (2024-06-21)	-37.15%

1 year (2023-12-22)	78.29%
2 years (2022-12-22)	-4.22%
3 years (2021-12-22)	4.84
5 years (2019-12-20)	15.53

BeyondSpring financials

Revenue TTM	$1.9 million
Gross profit TTM	$1.4 million
Return on assets TTM	-39.64%
Return on equity TTM	-310.48%
Profit margin	0%
Book value	$-0.75
Market Capitalization more info button	$68.9 million

TTM: trailing 12 months

BeyondSpring share dividends

We're not expecting BeyondSpring to pay a dividend over the next 12 months.

BeyondSpring share price volatility

Over the last 12 months, BeyondSpring's shares have ranged in value from as little as $0.7777 up to $4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeyondSpring's is 0.299. This would suggest that BeyondSpring's shares are less volatile than average (for this exchange).

BeyondSpring overview

BeyondSpring Inc. , a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration.

Frequently asked questions

null
What percentage of BeyondSpring is owned by insiders or institutions?
Currently 25.539% of BeyondSpring shares are held by insiders and 13.792% by institutions. How many people work for BeyondSpring?
Latest data suggests 36 work at BeyondSpring. When does the fiscal year end for BeyondSpring?
BeyondSpring's fiscal year ends in December. Where is BeyondSpring based?
BeyondSpring's address is: 100 Campus Drive, Florham Park, NJ, United States, 07932 What is BeyondSpring's ISIN number?
BeyondSpring's international securities identification number is: KYG108301006 What is BeyondSpring's CUSIP number?
BeyondSpring's Committee on Uniform Securities Identification Procedures number is: G10830100